VECIMA/VECTOR/LIBERTY
17.5.2021 14:02:57 CEST | Business Wire | Press release
Liberty Global (NASDAQ: LBTYA, LBTYB and LBTYK), one of the world’s leading converged video, broadband and communications companies, continues the rollout of Remote PHY (R-PHY) technology in Europe, with the support of Vector Technologies and Vecima Networks Inc. (TSX: VCM). The partnership will start Liberty Global on a path to delivering 10Gbps connectivity throughout their European footprint.
The jointly developed, next-generation R-PHY solution packages Vecima’s Entra ERM112 RPD (Remote PHY Device) module in Vector Technologies’ ACCERON Compact R-PHY Node. The fully interoperable solution accelerates deployment of Distributed Access Architecture (DAA) in Liberty Global's access network and enables Liberty Global to fulfil their 10G network roadmap, delivering the next great leap in speed, capacity, and low latency.
“The partnership with Vecima and Vector Technologies was a natural extension of our ongoing business activities, mainly focused on our mission to create the next-generation broadband networks in Europe,” said Seamus Gallagher, Liberty Global’s VP of Access Network Strategy. “Currently, we have over 19 million homes connected throughout Europe with speeds of 1Gbps. DAA brings many benefits, such as increased network bandwidth and less equipment in the headend and hub by enabling a multi-service - video/data/voice/mobile backhaul - unified, fiber core network. We are excited to continue our gigabit rollout with a solution that helps avoid vendor lock-in and supports multi-vendor interoperability.”
Liberty Global, with support from Vecima and Vector Technologies, plans to complete field trials in Autumn 2021 in their Western and Central Europe operating companies. The trials showcase R-PHY’s operational efficiency and the planned deployment cement Liberty Global as a worldwide leader in next-gen gigabit broadband.
‟We are excited to partner with both Liberty Global and Vector Technologies to leverage our Entra DAA solutions to transform consumer experiences in homes, businesses, and anywhere that people connect,” said Clay McCreery, Chief Operating Officer at Vecima. “Utilizing existing network infrastructures, Vecima is committed to building and delivering the industry’s most innovative cable access solutions that will deliver ground-breaking speed and capacity. Liberty is one of the leading operators in the world, and we’re proud to help enable their strategic vision.”
Liberty Global requirements included a solution that was fully interoperable with their deployed CCAP Core platforms. The Vecima ERM112 RPD module gives Liberty Global the freedom to source access network elements from multiple vendors, enhancing cost efficiency and accelerating time to market. Vector Technologies acted as the integrator for the project and performed all necessary tests at its DAA and DOCSIS laboratories.
"Vector Technologies and Vecima built a solution that supports a standards-based, multi-vendor environment. We believe that openness is the key to building the access network of the future, and we are committed to building scalable, secure, and simple solutions to manage network solutions that avoid vendor lock-in scenarios," said Maciej Muzalewski, CTO of Vector Technologies. “ We performed all the essential tests at our high-tech laboratories, which we built to support future DOCSIS and DAA implementations. We are delighted to continue our partnership with Liberty Global as an integrator, helping them forge ahead to gigabit speeds across their footprint."
Bridging the new 10G digital fiber CIN networks and the legacy RF coax plant, the combined Vector Technologies and Vecima solution supports architectures that push fiber deeper into the network, allowing operators to leverage existing network capacity and deliver increased bandwidth to subscribers.
About Liberty Global
Liberty Global (NASDAQ: LBTYA, LBTYB and LBTYK) is one of the world’s leading converged video, broadband and communications companies, with operations in seven European countries under the consumer brands Virgin Media, Telenet, UPC, the combined Sunrise UPC, as well as VodafoneZiggo, which is owned through a 50/50 joint venture. Our substantial scale and commitment to innovation enable us to invest in the infrastructure and digital platforms that empower our customers to make the most of the digital revolution.
Liberty Global delivers market-leading products through next-generation networks that connect customers subscribing to 50 million broadband, video, fixed and mobile telephony services across our brands. We also have significant investments in ITV, All3Media, ITI Neovision, LionsGate, the Formula E racing series and several regional sports networks.
For more information, please visit www.libertyglobal.com
.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is a global leader focused on developing integrated hardware and scalable software solutions for broadband access, content delivery, and telematics. We enable the world’s leading innovators to advance, connect, entertain, and analyze. We build technologies that transform content delivery and storage, enable high‑capacity broadband network access, and streamline data analytics.
Further information about Vecima’s Entra solution is available at https://vecima.com/solutions/distributed-access/
. Or visit our website at www.vecima.com
.
About Vector Technologies
Vector Technologies acts as a European competence center for the world’s largest Multiple System Operators and support them in network transformation towards Distributed Access Architecture.
As an experienced partner, we:
- integrate, optimize and design solutions for Next Generation Access Networks
- define the best directions of technological development in the area of Distributed Access Architecture (DAA) or Passive Optical Networks (PON) and Software-Defined Networking (SDN)
- support Multiple System Operators in the efficient technology migrations
- help operators in increasing efficiency and availability of provided services
- have proven field experience in managing turnkey projects for Remote-PHY, DAA, DOCSIS 3.1 and DOCSIS 3.0
For more information, updates and useful links, please visit our website: https://vectortechnologies.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005226/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom